1. Home
  2. RYM vs IMMP Comparison

RYM vs IMMP Comparison

Compare RYM & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RYM

RYTHM Inc.

HOLD

Current Price

$26.58

Market Cap

60.2M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.45

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYM
IMMP
Founded
2016
1987
Country
United States
Australia
Employees
141
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.2M
58.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
RYM
IMMP
Price
$26.58
$0.45
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
10.9K
21.8M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.00
$0.29
52 Week High
$53.65
$3.53

Technical Indicators

Market Signals
Indicator
RYM
IMMP
Relative Strength Index (RSI) 48.53 33.72
Support Level $15.26 $0.29
Resistance Level $30.90 $1.05
Average True Range (ATR) 2.95 0.03
MACD -0.73 0.03
Stochastic Oscillator 13.92 14.24

Price Performance

Historical Comparison
RYM
IMMP

About RYM RYTHM Inc.

Rythm Inc is a USA Based company. The company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: